Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CHR710
MIFTS: 45

Chronic Spontaneous Urticaria

Categories: Skin diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Chronic Spontaneous Urticaria

About this section

MalaCards integrated aliases for Chronic Spontaneous Urticaria:

Name: Chronic Spontaneous Urticaria 12 15
Chronic Idiopathic Urticaria 12

Classifications:

MalaCards categories:
Anatomical: Skin diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:0080749
Sources

Summaries for Chronic Spontaneous Urticaria

About this section
Disease Ontology : 12 A chronic urticaria that is characterized by urticaria independent of any exogenous stimulus.

MalaCards based summary : Chronic Spontaneous Urticaria, also known as chronic idiopathic urticaria, is related to urticaria and chronic urticaria. An important gene associated with Chronic Spontaneous Urticaria is FCER1A (Fc Fragment Of IgE Receptor Ia), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Omalizumab and Benralizumab have been mentioned in the context of this disorder. Affiliated tissues include skin, thyroid and endothelial, and related phenotypes are hematopoietic system and homeostasis/metabolism

Wikipedia : 74 Hives, also known as urticaria, is a kind of skin rash with red, raised, itchy bumps. They may also burn... more...

Sources

Related Diseases for Chronic Spontaneous Urticaria

About this section

Diseases related to Chronic Spontaneous Urticaria via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 705)
# Related Disease Score Top Affiliating Genes
1 urticaria 32.2 TNF IL6 IL31 FCER1A CRP
2 chronic urticaria 31.5 TNF PTGDR2 IL6 FCER1A CRP
3 chronic inducible urticaria 31.2 TSLP IL31 FCER1A
4 vasculitis 30.8 TNF IL6 IL17A CRP
5 hashimoto thyroiditis 30.6 IL6 IL18 IL17A IFNG
6 anxiety 30.3 TNF TAC1 IL6 CRP
7 food allergy 30.3 TNF IL17A IFNG CXCL8
8 mental depression 30.2 TNF IL6 CRP
9 nasopharyngitis 30.2 TNF IL17A CRP
10 thyroiditis 30.2 TNF IL6 IL2 IL17A IFNG CRP
11 pustulosis of palm and sole 30.1 TNF IL17A CXCL8 CRP
12 pharyngitis 30.0 TNF IL6 CXCL8 CRP
13 apnea, obstructive sleep 30.0 TNF IL6 CXCL8 CRP
14 atrophic gastritis 30.0 TNF IL6 CXCL8
15 helicobacter pylori infection 29.9 TNF CXCL8 CCL5
16 wells syndrome 29.9 IL2 CXCL8 CRP
17 alopecia areata 29.9 TNF IL6 IL2 IL17A IFNG
18 exanthem 29.8 TNF IL6 IL2 IL18 IFNG CXCL8
19 migraine with or without aura 1 29.8 TNF TACR1 TAC1 IL6 CRP
20 severe combined immunodeficiency 29.8 IL6 IL2 IL17A IFNG
21 constipation 29.8 TACR1 TAC1 IL6 CRP
22 hepatitis b 29.8 TNF IL6 IFNG CXCL8
23 sleep apnea 29.7 TNF TAC1 IL6 CXCL8 CRP
24 allergic disease 29.7 TSLP TNF IL6 IL33 IL2 IL18
25 sleep disorder 29.7 TNF TAC1 IL6 CXCL8 CRP
26 viral hepatitis 29.6 TNF IL6 IL2 IFNG CRP
27 churg-strauss syndrome 29.5 TNF IL2 IL17A CXCL8
28 familial mediterranean fever 29.5 TNF IL6 IL18 IL17A CXCL8 CRP
29 allergic rhinitis 29.5 MS4A2 IL18 IL17A IFNG FCER1A CXCL8
30 common variable immunodeficiency 29.5 TNF IL6 IL2 IFNG
31 vascular disease 29.4 TNF IL6 IL2 IL18 IFNG CRP
32 rhinitis 29.4 TSLP TNF IL6 IL33 IL17A IFNG
33 hypereosinophilic syndrome 29.4 IL2 IFNG CXCL8 CCL5
34 gastritis 29.2 TNF IL6 IL17A CXCL8 CCL5
35 neutropenia 29.1 TNF IL6 IL2 IFNG CXCL8 CRP
36 allergic asthma 29.0 TSLP MS4A2 IL18 IL17A IFNG CXCL8
37 celiac disease 1 29.0 TNF IL6 IL2 IL18 IL17A IFNG
38 allergic contact dermatitis 28.9 TNF TACR1 IL6 IL33 IL31 IL17A
39 arthritis 28.9 TNF IL6 IL18 IL17A IFNG CXCL8
40 brucellosis 28.8 TNF IL6 IL2 IL18 IL17A IFNG
41 crohn's disease 28.8 TNF IL6 IL2 IL18 IL17A IFNG
42 type 1 diabetes mellitus 28.8 TNF IL6 IL2 IL18 IL17A IFNG
43 thrombocytopenia 28.8 TNF IL6 IL2 IL18 IL17A IFNG
44 body mass index quantitative trait locus 11 28.8 TNF IL6 IL18 IL17A CXCL8 CRP
45 autoimmune disease 28.7 TNF IL6 IL2 IL18 IL17A IFNG
46 proteasome-associated autoinflammatory syndrome 1 28.6 TNF IL6 IL18 IL17A IFNG CXCL8
47 immune deficiency disease 28.6 TNF IL6 IL2 IL18 IL17A IFNG
48 common cold 28.6 TSLP TNF PTGDR2 IL6 IL33 IL17A
49 skin disease 28.5 TSLP TNF TACR1 TAC1 IL6 IL31
50 multiple sclerosis 28.5 TNF IL6 IL2 IL18 IL17A IFNG

Graphical network of the top 20 diseases related to Chronic Spontaneous Urticaria:



Diseases related to Chronic Spontaneous Urticaria
Sources

Symptoms & Phenotypes for Chronic Spontaneous Urticaria

About this section

MGI Mouse Phenotypes related to Chronic Spontaneous Urticaria:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.2 C5AR1 CCL5 FCER1A IFNG IL17A IL18
2 homeostasis/metabolism MP:0005376 10.1 C5AR1 CRP FCER1A IFNG IL17A IL18
3 immune system MP:0005387 10.03 C5AR1 CCL5 CRP FCER1A IFNG IL17A
4 digestive/alimentary MP:0005381 9.97 IFNG IL17A IL18 IL2 IL33 IL6
5 integument MP:0010771 9.61 IFNG IL17A IL18 IL33 IL6 TAC1
6 respiratory system MP:0005388 9.23 IFNG IL17A IL2 IL33 IL6 TACR1
Sources

Drugs & Therapeutics for Chronic Spontaneous Urticaria

About this section

Drugs for Chronic Spontaneous Urticaria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 67)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Omalizumab Approved, Investigational Phase 4 242138-07-4
2 Benralizumab Approved, Investigational Phase 4 1044511-01-4
3
Loratadine Approved, Investigational Phase 4 79794-75-5 3957
4
Tranexamic Acid Approved Phase 4 1197-18-8 5526
5
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
6
Cetirizine Approved Phase 4 83881-51-0 2678
7
Desloratadine Approved, Investigational Phase 4 100643-71-8 124087
8 Dermatologic Agents Phase 4
9 Respiratory System Agents Phase 4
10 Anti-Asthmatic Agents Phase 4
11 Immunoglobulins Phase 4
12 Antibodies Phase 4
13 Antibodies, Monoclonal Phase 4
14 Immunoglobulin E Phase 4
15 Immunoglobulins, Intravenous Phase 4
16 Hemostatics Phase 4
17 Coagulants Phase 4
18 Antifibrinolytic Agents Phase 4
19 Cholinergic Agents Phase 4
20 Histamine Antagonists Phase 4
21 Histamine H1 Antagonists Phase 4
22 Anti-Allergic Agents Phase 4
23 Neurotransmitter Agents Phase 4
24
Histamine Phosphate Phase 4 51-74-1 65513
25 Histamine H1 Antagonists, Non-Sedating Phase 4
26 Cholinergic Antagonists Phase 4
27
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
28
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
29
Levocetirizine Approved Phase 3 130018-77-8 1549000
30
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
31
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
32
tannic acid Approved Phase 3 1401-55-4
33
Promethazine Approved, Investigational Phase 3 60-87-7 4927
34
Cyproheptadine Approved Phase 3 129-03-3 2913
35
Vitamin D3 Approved, Nutraceutical Phase 3 67-97-0 6221 5280795
36
Ergocalciferol Approved, Nutraceutical Phase 3 50-14-6 5280793
37
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
38
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
39 Trace Elements Phase 3
40 Vitamin D2 Phase 3
41 Ergocalciferols Phase 3
42 Vitamins Phase 3
43 Calcium, Dietary Phase 3
44 Calciferol Phase 3
45 Nutrients Phase 3
46 Micronutrients Phase 3
47 Folic Acid Antagonists Phase 3
48 Vitamin B Complex Phase 3
49 Antimetabolites Phase 3
50 Vitamin B9 Phase 3

Interventional clinical trials:

(show top 50) (show all 73)
# Name Status NCT ID Phase Drugs
1 A Randomized, Double-Blind, Active-Controlled, Parallel-Group Study to Compare the Efficacy and Safety of Desloratadine 5mg (Denosin®) With Levocetirizine 5mg (Xyzal®) in the Treatment of Chronic Idiopathic Urticaria Patients Unknown status NCT00346606 Phase 4 Denosin® and Xyzal®
2 XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria Completed NCT02392624 Phase 4 Omalizumab;Placebo
3 A Phase IV, Multicenter, Single-arm and Open-label Study With Omalizumab (Xolair®) in Chronic Spontaneous Urticaria (CSU) Patients Who Remain Symptomatic Despite Antihistamine (H1) Treatment Completed NCT02550106 Phase 4 OMALIZUMAB
4 A Comparative Study on Clinical Efficacy and Safety of Levocetirizine 5 mg Oral Capsules Once Daily in the Morning vs. Desloratadine 5 mg Oral Capsules Once Daily in the Morning in Patients Suffering From Chronic Idiopathic Urticaria (CIU) Completed NCT00264303 Phase 4 Levocetirizine;Desloratadine
5 A Study of the Efficacy, Safety, and Quality of Life (QOL) in Patients With Chronic Idiopathic Urticaria Dosed With AERIUS Tablets (Desloratadine 5 mg, 10 mg, or 20 mg Once Daily) Completed NCT00536380 Phase 4 5-mg Desloratadine;10-mg Desloratadine;20-mg Desloratadine
6 Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monocloncal Antibody Completed NCT03183024 Phase 4
7 A Comparative Double-Blind, Double- Dummy Study of Desloratadine (DL) 5 MG Once Daily, Cetirizine 10 MG Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (CIU) Completed NCT00751218 Phase 4 desloratadine;placebo;cetirizine
8 An Open-Label Study of the Effects of Desloratadine (Aerius.) Treatment on the Quality of Life of Patients With Chronic Idiopathic Urticaria Completed NCT00795522 Phase 4 Desloratadine
9 Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria Completed NCT03111628 Phase 4 Omalizumab
10 Effect of Omalizumab (Xolair) on the Basophil Proteome in Patients With Chronic Idiopathic Urticaria Completed NCT01701583 Phase 4 Omalizumab
11 A Pilot, Multicenter, Double-blind Randomized Study for Comparison of Aerius® "Continuous Treatment" Versus Aerius® "PRN Regimen" on Chronic Idiopathic Urticaria Patient Quality of Life Completed NCT00783354 Phase 4 desloratadine;desloratadine
12 Efficacy and Safety of Levocetirizine Alone or in Combination With Tranexamic Acid in the Treatment of Spontaneous Chronic Urticaria. Multicentric Controlled Randomized Study in Cross-over, Double-blind Recruiting NCT03789422 Phase 4 association of levocetirizine and tranexamic acid;Levocetirizine only
13 A Comparative Double-blind, Double-dummy Study of Desloratadine (DL) 5 mg Once Daily, Cetirizine 10 mg Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (CIU) Terminated NCT00751166 Phase 4 Desloratadine;Cetirizine;placebo
14 High Dose Vitamin D Supplementation in Treatment of Chronic Spontaneous Urticaria Unknown status NCT02873364 Phase 3 Vitamin D3 (High dose);Vitamin D3 (Low dose)
15 Efficacy and Safety of Omalizumab in Chronic Idiopathic Urticaria Unknown status NCT02166151 Phase 3 Omalizimab
16 A Phase III, Multicenter, Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria Who Remain Symptomatic Despite Antihistamine Treatment (H1) Completed NCT01292473 Phase 3 Placebo;Omalizumab
17 A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Xolair® (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1) Completed NCT01287117 Phase 3 Omalizumab;Placebo
18 OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in CSU Patients Completed NCT02161562 Phase 3 omalizumab;omalizumab
19 A Randomized, Double-blind, Placebo-controlled, 28-week Treatment With a 8 Week Follow-up to Investigate the Impact of Omalizumab on Quality of Life Measures and the Incidence and Severity of Angioedema Despite H1-antihistamine Therapy. Completed NCT01723072 Phase 3 Placebo
20 Efficacy of Levocetirizine Fourfold Dosage in Chronic Spontaneous Urticaria Resistant to the Licensed Dosage Completed NCT02372604 Phase 3 Levocetirizine (as levocetirizine dihydrochloride), 5mg ( then 20 mg) per day . Oral administration.;Levocetirizine, (as levocetirizine dihydrochloride) 20 mg ( then 5 mg) per day. Oral administration.
21 A Phase III Study to Evaluate the Efficacy and Safety of Xolair® (Omalizumab) in Chinese Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment Completed NCT03328897 Phase 3 Omalizumab;Placebo
22 A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Omalizumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite H1 Antihistamine Therapy Completed NCT02329223 Phase 3
23 Phase 3 Study, Exploratory, Disease Activity Controlled Dose Escalating Study to Assess the Efficacy, and Safety of Treatment With Bilastine 20 mg, 40 mg and 80 mg in Chronic Spontaneous Urticaria. Completed NCT02213367 Phase 3 Bilastine;Bilastine;Bilastin
24 Multiple-Dose Safety and Tolerance Study of Desloratadine in Atopic Pediatric Subjects and Pediatric Subjects With Chronic Idiopathic Urticaria, Ages >=2 to <12 Years, Who Are Poor Metabolizers of Desloratadine Completed NCT00757562 Phase 3 desloratadine;Placebo
25 A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists Completed NCT01264939 Phase 3 Omalizumab;Placebo;H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist;Diphenhydramine
26 Randomized Clinical Trial Evaluating the Efficacy of Methotrexate in Addition to Anti-H1 Versus Placebo and Anti-H1 in the Treatment of Severe Chronic Idiopathic Urticaria Completed NCT01960283 Phase 3 Methotrexate (Novatrex ®) + anti-H1;Placebo + anti-H1
27 Double-blind, Randomised, Placebo-controlled, Phase III Study Comparing the Efficacy and Safety of Bilastine 20 mg Once Daily and Levocetirizine 5 mg for the Treatment of Chronic Idiopathic Urticaria Completed NCT00421109 Phase 3 Bilastine;Levocetirizine;Placebo
28 A Study Evaluating the Efficacy and Safety of 5 mg Levocetirizine Oral Tablets, Once Daily Versus 10 mg Loratadine Oral Tablets, Once Daily for the Treatment of Chronic Idiopathic Urticaria (CIU) Completed NCT00525382 Phase 3 levocetirizine dihydrochloride
29 A Multi-center, Double-blinded and Open-label Extension Study to Evaluate the Efficacy and Safety of Ligelizumab as Retreatment, Self-administered Therapy and Monotherapy in Chronic Spontaneous Urticaria Patients Who Completed Studies CQGE031C2302, CQGE031C2303, CQGE031C2202 or CQGE031C1301 Recruiting NCT04210843 Phase 3 Ligelizumab
30 A Multi-center, Randomized, Double-blind, Active and Placebo-controlled Study to Investigate the Efficacy and Safety of Ligelizumab (QGE031) in the Treatment of Chronic Spontaneous Urticaria (CSU) in Adolescents and Adults Inadequately Controlled With H1-antihistamines Recruiting NCT03580369 Phase 3
31 A Multi-center, Randomized, Double-blind, Active and Placebo-controlled Study to Investigate the Efficacy and Safety of Ligelizumab (QGE031) in the Treatment of Chronic Spontaneous Urticaria (CSU) in Adolescents and Adults Inadequately Controlled With H1-antihistamines Recruiting NCT03580356 Phase 3
32 A Multi-center, Open-label Study to Investigate the Safety/Tolerability and Efficacy of Ligelizumab (QGE031) in the Treatment of Adult Japanese Patients With Chronic Spontaneous Urticaria (CSU) Inadequately Controlled With H1 Antihistamines Recruiting NCT03907878 Phase 3
33 Master Protocol of Two Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients naïve to Omalizumab and in Patients Who Are Intolerant or Incomplete Responders to Omalizumab Recruiting NCT04180488 Phase 3 Dupilumab SAR231893;Placebo;non sedating H1-antihistamine
34 A Double-blind, Randomized, Active-controlled, Parallel Group, Phase 3 Study to Compare Efficacy and Safety of CT-P39 and Xolair in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment Not yet recruiting NCT04426890 Phase 3
35 A Multi-center, Randomized, Double Blind, Dose Escalating Phase III Study on the Efficacy, Safety and Long Term Outcome of Continuous vs. on Demand Treatment of Chronic Spontaneous Urticaria With Rupatadine. Terminated NCT02358265 Phase 3 10 mg Rupatadine on demand;10 mg Rupatadine;20 mg Rupatadine;10 mg Rupatadine on demand (sham updosing to 20 mg)
36 A 6-Week Multicentre, Double-Blind, Randomised, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Rupatadine 10 and 20 Mg in the Treatment of Chronic Idiopathic Urticaria (CIU): a Phase III Clinical Trial Terminated NCT00199251 Phase 3 RUPATADINE
37 A 6 Week Randomized, Double Blind, Placebo-controlled Study With a 6 Week Open Label Extension to Assess the Efficacy of Etanercept in the Treatment of Chronic Idiopathic Urticaria Withdrawn NCT01030120 Phase 2, Phase 3 etanercept;placebo
38 A Phase II Randomized Double-Blind Placebo Controlled Single Center Study of Canakinumab Treatment of Adult Patients With Moderate to Severe Chronic Idiopathic Urticaria Unknown status NCT01635127 Phase 2 Canakinumab;Placebo
39 An Open Label, Multicenter, Extension Study to Evaluate the Long-term Safety of QGE031 240 mg s.c. Given Every 4 Weeks for 52 Weeks in Chronic Spontaneous Urticaria Patients Who Completed Study CQGE031C2201 Completed NCT02649218 Phase 2
40 A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU) Completed NCT02477332 Phase 2
41 A Study of Quilizumab Versus Placebo in Patients With Refractory Chronic Spontaneous Urticaria Completed NCT01987947 Phase 2 Placebo;Quilizumab
42 A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Pilot and Dose-Ranging Study of GDC-0853 in Patients With Refractory Chronic Spontaneous Urticaria (CSU). Completed NCT03137069 Phase 2 GDC-0853;Placebo
43 A Phase IIa, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of the CRTh2 Antagonist AZD1981 in Patients With Chronic Idiopathic Urticaria (CIU) Who Are Refractory to H1 Antihistamines Completed NCT02031679 Phase 2 AZD1981;Placebo
44 A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1) Completed NCT00866788 Phase 2 omalizumab;placebo;H1 antihistamines;Diphenhydramine
45 A Phase II, Multi-centre, Randomized, Double Blind, Placebo-controlled Study to Determine the Mode of Action of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1) Completed NCT01599637 Phase 2 IGE025;placebo
46 A Phase 2b Multinational, Randomised, Double-blind, Parallel- Group, 24-week Placebo-controlled Study With 28-week Extension to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO) Recruiting NCT04612725 Phase 2
47 An Open-label, Multicenter, Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Eligible Subjects With CSU Who Have Participated in Preceding Studies With LOU064 Recruiting NCT04109313 Phase 2 LOU064
48 A Multicenter, Randomized, Double-blind, Placebo- Controlled Phase 2b Dose-finding Study to Investigate the Efficacy, Safety and Tolerability of LOU064 in Adult Chronic Spontaneous Urticaria (CSU) Patients Inadequately Controlled by H1-antihistamines Recruiting NCT03926611 Phase 2 LOU064 Arm 1;LOU064 Arm 2;LOU064 Arm 3;LOU064 Arm 4;LOU064 Arm 5;LOU064 Arm 6;Placebo arm
49 A Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-concept Phase 2, 16-week Treatment Study With a 16 Week Follow-up Period to Assess the Efficacy and Safety of Dupilumab (Anti-IL4Ra) in Adult Patients With Chronic Spontaneous Urticaria Despite H1-antihistamine Treatment. Recruiting NCT03749135 Phase 2 Dupilumab;Placebo
50 A Phase 2a Placebo-controlled, Open-label, Single Center Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol (CBD) as a Steroid-sparing Therapy in Chronic Spontaneous Urticaria (CSU) Patients Recruiting NCT04439955 Phase 2 CBD

Search NIH Clinical Center for Chronic Spontaneous Urticaria

Sources

Genetic Tests for Chronic Spontaneous Urticaria

About this section
Sources

Anatomical Context for Chronic Spontaneous Urticaria

About this section

MalaCards organs/tissues related to Chronic Spontaneous Urticaria:

40
Skin, Thyroid, Endothelial, Whole Blood, Neutrophil, T Cells, Monocytes
Sources

Publications for Chronic Spontaneous Urticaria

About this section

Articles related to Chronic Spontaneous Urticaria:

(show top 50) (show all 1673)
# Title Authors PMID Year
1
Total IgE as a Marker for Chronic Spontaneous Urticaria. 61
33474856 2021
2
Rotational Thromboelastometry Profile in Children With Chronic Spontaneous Urticaria. 61
32282649 2021
3
Histopathology of chronic spontaneous urticaria with occasional bruising lesions is not significantly different from urticaria with typical wheals. 61
33595130 2021
4
It is never too late to treat chronic spontaneous urticaria with omalizumab: Real-life data from a multicenter observational study focusing on elderly patients. 61
33527659 2021
5
Plasma adenosine is linked to disease activity and response to treatment in patients with chronic spontaneous urticaria. 61
32687639 2021
6
Increased grey matter volume and associated resting-state functional connectivity in chronic spontaneous urticaria: A structural and functional MRI study. 61
33549611 2021
7
PEG that reaction: A case series of allergy to polyethylene glycol. 61
33543766 2021
8
Self-administration of omalizumab: why not? A literature review and expert opinion. 61
33504237 2021
9
The Effects of Antibiotics for Helicobacter pylori Eradication or Dapsone on Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis. 61
33557074 2021
10
Predictors of treatment response in chronic spontaneous urticaria. 61
33539587 2021
11
Dupilumab use in dermatologic conditions beyond atopic dermatitis - a systematic review. 61
31693426 2021
12
Clinical variables of severe Chronic Spontaneous Urticaria from total IgE standpoint: a retrospective study. 61
33555151 2021
13
Association of UBASH3A polymorphism with chronic spontaneous urticaria in a Chinese Han population. 61
33583125 2021
14
Positive Effect of Helicobacter pylori Treatment on Outcome of Patients With Chronic Spontaneous Urticaria. 61
32940336 2021
15
Comparative Efficacy and Acceptability of Licensed Dose Second-Generation Antihistamines in Chronic Spontaneous Urticaria: A Network Meta-Analysis. 61
32916325 2021
16
Mas-related G protein-coupled receptor X2 and its activators in dermatologic allergies. 61
33071069 2021
17
Biomarkers of chronic spontaneous urticaria and their clinical implications. 61
33496195 2021
18
The global burden of chronic urticaria for the patient and society. 61
32956489 2021
19
miR-126-3p and miR-16-5p as novel serum biomarkers for disease activity and treatment response in symptomatic dermographism. 61
33264723 2021
20
Novel Therapeutic Approaches and Targets for Treatment of Chronic Urticaria: New Insights and Promising Targets for a Challenging Disease. 61
32603278 2021
21
CME suggestions for pediatricians, allergists, and dermatologists, directed by an online survey on urticaria knowledge. 61
33528934 2021
22
The association of chronic spontaneous urticaria (CSU) with anxiety and depression: a nationwide cohort study. 61
32270319 2021
23
Biologicals in atopic disease in pregnancy: An EAACI position paper. 61
32189356 2021
24
Targeted Molecular Therapies in Allergy and Rhinology. 61
33138725 2021
25
High waist circumference rather than high body mass index may be a predictive risk factor for the longer disease duration of chronic spontaneous urticaria. 61
33479357 2021
26
Immunologic Pathophysiology and Airway Remodeling Mechanism in Severe Asthma: Focused on IgE-Mediated Pathways. 61
33419185 2021
27
Chronic Urticaria in Children - New Insights from a Large Cohort. 61
33502063 2021
28
Successful treatment of intractable chronic spontaneous urticaria with omalizumab in a patient with ovarian cancer. 61
33459258 2021
29
Analysis of the long-term economic burden of omalizumab on patients with chronic spontaneous urticaria. 61
33029864 2021
30
Chronic spontaneous urticaria treated with omalizumab: what differentiates early from late responders? 61
32378398 2021
31
Canakinumab Lacks Efficacy in Treating Adult Patients with Moderate to Severe Chronic Spontaneous Urticaria in a Phase II Randomized Double-Blind Placebo-Controlled Single-Center Study. 61
32827729 2021
32
D-dimer concentrations in acute urticaria in children. 61
33528937 2021
33
Natural history and predictors of recovery in children with chronic spontaneous urticaria. 61
32460386 2021
34
Role of Helicobacter pylori Eradication in Chronic Spontaneous Urticaria: A Propensity Score Matching Analysis. 61
33584099 2021
35
Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines. 61
32767573 2021
36
Hematologic parameters as biomarkers for antihistamine and omalizumab resistance in chronic spontaneous urticaria. 61
33404397 2021
37
Fatigue Is Common and Predicted by Female Gender and Sleep Disturbance in Patients with Chronic Spontaneous Urticaria. 61
32858240 2021
38
Efficacy and tolerability of the updosing of second-generation non-sedating H1 antihistamines in children with chronic spontaneous urticaria. 61
32745323 2021
39
Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both. 61
33510832 2021
40
A Comprehensive Approach to Urticaria: From Clinical Presentation to Modern Biological Treatments Through Pathogenesis. 61
33385176 2021
41
Autologous serum skin test reactions in chronic spontaneous urticaria differ from heterologous cell reactions. 61
33475206 2021
42
SELE Downregulation Suppresses Mast Cell Accumulation to Protect against Inflammatory Response in Chronic Idiopathic Urticaria. 61
33285544 2021
43
Real-life, long-term data on efficacy, safety, response and discontinuation patterns of omalizumab in a Greek population with chronic spontaneous urticaria. 61
33258453 2020
44
Extracellular vesicle microRNAs as predictors of response to omalizumab in chronic spontaneous urticaria. 61
33314187 2020
45
The Fcε receptor I pathway is crucial but not exclusive for basophil activation in patients with autoimmune forms of chronic spontaneous urticaria. 61
32491222 2020
46
Successful treatment of normocomplementemic urticarial vasculitis with omalizumab: A report of three cases and literature review. 61
30660172 2020
47
Clinical predictive factors of unresponsiveness to omalizumab in patients with chronic spontaneous urticaria. 61
32531805 2020
48
Treatment of chronic spontaneous urticaria with benralizumab: Report of primary endpoint per-protocol analysis and exploratory endpoints. 61
33326617 2020
49
High-Dose Omalizumab versus Ligelizumab for the Treatment of Chronic Spontaneous Urticaria: Do Not We Need a Head-To-Head Comparison? 61
33321510 2020
50
Increased serum IL-31 levels in chronic spontaneous urticaria and psoriasis with pruritic symptoms. 61
33305054 2020
Sources

Variations for Chronic Spontaneous Urticaria

About this section
Sources

Expression for Chronic Spontaneous Urticaria

About this section
Search GEO for disease gene expression data for Chronic Spontaneous Urticaria.
Sources

Pathways for Chronic Spontaneous Urticaria

About this section

Pathways related to Chronic Spontaneous Urticaria according to GeneCards Suite gene sharing:

(show top 50) (show all 63)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 13.98 TNF MS4A2 IL6 IL33 IL31 IL24
2
TGF-Beta Pathway 63
Show member pathways
 13.59 TNF IL6 IL24 IL2 IL18 IL17A
3
PEDF Induced Signaling 63
Show member pathways
 13.52 TSLP TNF IL6 IL33 IL31 IL24
4
Akt Signaling 63
Show member pathways
 13.45 TNF IL6 IL24 IL2 IL18 IL17A
5
PAK Pathway 63
Show member pathways
 13.34 TNF IL6 IL24 IL2 IL18 IL17A
6
Cytokine Signaling in Immune system 65
Show member pathways
 13.28 TNF IL6 IL33 IL31 IL24 IL2
7
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.09 TNF IL6 IL2 IFNG CXCL8 CCL5
8
Allograft rejection 36 1
Show member pathways
 12.89 TNF MS4A2 IL6 IL2 IL17A IFNG
9
Measles 36
Show member pathways
 12.87 TNF IL6 IL33 IL2 IL18 IFNG
10
Toll-Like receptor Signaling Pathways 64
Show member pathways
 12.75 TNF IL6 IL33 IL18 CXCL8
11
Immune response NFAT in immune response 23
Show member pathways
 12.7 TNF MS4A2 IL2 IL18 IFNG FCER1A
12
Th17 cell differentiation 36
Show member pathways
 12.66 TNF IL6 IL2 IL18 IL17A IFNG
13
Immune response IL-23 signaling pathway 23
Show member pathways
 12.65 TNF IL6 IL24 IL2 IL18 IL17A
14
T cell receptor signaling pathway 36
Show member pathways
 12.64 TNF IL6 IL2 IL17A IFNG
15
NF-kappaB Signaling 4
12.61 TNF IL2 IL17A IFNG CCL5
16
JAK-STAT signaling pathway 36
Show member pathways
 12.48 TSLP IL6 IL24 IL2 IFNG
17
Shigellosis 36
12.42 TNF IL18 CXCL8 CCL5
18
Folate Metabolism 1
Show member pathways
 12.41 TNF IL6 IL2 IFNG CRP CCL5
19
IL-17 Family Signaling Pathways 64
Show member pathways
 12.4 TNF IL6 IL17A IFNG CXCL8
20
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.34 TNF IL6 IL2 IL18 IL17A IFNG
21
Toll Comparative Pathway 63
Show member pathways
 12.33 TNF IL6 IFNG CXCL8
22
NOD-like receptor signaling pathway 36
12.31 TNF IL6 IL18 CXCL8 CCL5
23
Tuberculosis 36
12.27 TNF IL6 IL18 IFNG
24
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.25 TNF TACR1 TAC1 IL6 CXCL8
25
Bacterial infections in CF airways 23
Show member pathways
 12.23 TNF IL6 IFNG CXCL8
26
Chemokine Superfamily Pathway: Human/Mouse Ligand-Receptor Interactions 64
Show member pathways
 12.2 TNF IL6 IL24 IL2 IL18 CXCL8
27
Yersinia infection 36
12.16 TNF IL6 IL2 IL18 CXCL8
28
Interleukin-4 and 13 signaling 65
12.07 TNF IL6 IL18 IL17A CXCL8
29
Senescence and Autophagy in Cancer 1
12.02 IL6 IL24 IFNG CXCL8
30
Spinal Cord Injury 1
12.01 TNF TACR1 IL6 IL2 IFNG CXCL8
31
Amoebiasis 36
12 TNF IL6 IFNG CXCL8
32
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.95 TNF PTGDR2 IL6 IL2 IFNG FCER1A
33
Glucocorticoid receptor regulatory network 1
11.88 IL6 IL2 IFNG CXCL8
34
Th17 Differentiation Pathway 64
Show member pathways
 11.87 IL6 IL17A IFNG
35
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.84 TNF IL2 IFNG CXCL8
36
Dendritic Cells Developmental Lineage Pathway 64
11.83 TNF IL6 IL2 IFNG
37
Pertussis 36
11.78 TNF IL6 CXCL8
38
Lung fibrosis 1
11.75 TNF IL6 CXCL8 CCL5
39
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.72 TNF IL6 IL2 IFNG CXCL8
40
Legionellosis 36
11.69 TNF IL6 IL18 CXCL8
41
Downstream signaling in naive CD8+ T cells 1
Show member pathways
 11.68 TNF IL2 IFNG
42
Rheumatoid arthritis 36
11.67 TNF IL6 IL18 IL17A IFNG CXCL8
43
Photodynamic therapy-induced AP-1 survival signaling. 1
11.64 TNF IL6 IL2 IFNG
44
ATF-2 transcription factor network 1
11.63 IL6 IFNG CXCL8
45
Th1 Differentiation Pathway 64
Show member pathways
 11.61 TNF IL6 IL2 IL18 IL17A IFNG
46
Malaria 36
11.59 TNF IL6 IL18 IFNG CXCL8
47
Th2 Differentiation Pathway 64
11.58 IL33 IL31 IL2 IFNG
48
MSP-RON Signaling 63
11.57 TNF IL18 IFNG
49
Aryl Hydrocarbon Receptor Pathway 1
11.57 TNF IL2 IFNG
50
Interleukin-10 signaling 65
11.57 TNF IL6 IL18 CXCL8 CCL5
Sources

GO Terms for Chronic Spontaneous Urticaria

About this section

Cellular components related to Chronic Spontaneous Urticaria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 TSLP TNF TAC1 IL6 IL33 IL31
2 extracellular space GO:0005615 9.47 TSLP TNF TAC1 IL6 IL33 IL31

Biological processes related to Chronic Spontaneous Urticaria according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 10.23 TACR1 TAC1 PTGDR2 IL2 CXCL8 CCL5
2 positive regulation of gene expression GO:0010628 10.04 TNF IL6 IL33 IL18 IFNG CXCL8
3 cell-cell signaling GO:0007267 9.99 TAC1 IL2 IL18 IL17A CCL5
4 cellular response to lipopolysaccharide GO:0071222 9.97 TNF IL6 IL24 CXCL8
5 positive regulation of cytosolic calcium ion concentration GO:0007204 9.96 TACR1 TAC1 IL2 C5AR1
6 chemotaxis GO:0006935 9.96 PTGDR2 CXCL8 CCL5 C5AR1
7 cytokine-mediated signaling pathway GO:0019221 9.91 TNF IL6 IL31 IL24 IL2 IL18
8 immune response GO:0006955 9.9 TNF PTGDR2 MS4A2 IL6 IL2 IL18
9 defense response to Gram-negative bacterium GO:0050829 9.89 TSLP IL6 IL17A
10 cellular response to interleukin-1 GO:0071347 9.89 IL17A CXCL8 CCL5
11 neutrophil chemotaxis GO:0030593 9.88 CXCL8 CCL5 C5AR1
12 positive regulation of tumor necrosis factor production GO:0032760 9.88 IL6 IL33 IL17A IFNG
13 cellular response to organic cyclic compound GO:0071407 9.87 TNF IL18 CCL5
14 positive regulation of interferon-gamma production GO:0032729 9.87 TNF IL2 IL18
15 positive regulation of T cell proliferation GO:0042102 9.86 IL6 IL2 CCL5
16 regulation of insulin secretion GO:0050796 9.86 TNF IL6 IFNG CCL5
17 humoral immune response GO:0006959 9.85 TNF IL6 IFNG
18 positive regulation of cytokine production GO:0001819 9.85 TNF IL33 IFNG
19 defense response to Gram-positive bacterium GO:0050830 9.85 TNF IL6 IL17A CRP C5AR1
20 positive regulation of inflammatory response GO:0050729 9.85 TSLP TNF IL33 IL2 IL18 IFNG
21 extrinsic apoptotic signaling pathway GO:0097191 9.83 TNF IL33 IFNG
22 positive regulation of smooth muscle cell proliferation GO:0048661 9.83 TNF IL6 IL18 CCL5
23 positive regulation of JAK-STAT cascade GO:0046427 9.81 TNF IL6 CCL5
24 positive regulation of interleukin-1 beta production GO:0032731 9.81 TNF IL6 IL17A IFNG
25 lipopolysaccharide-mediated signaling pathway GO:0031663 9.8 TNF IL18 CCL5
26 microglial cell activation GO:0001774 9.8 TNF IFNG C5AR1
27 positive regulation of chemokine production GO:0032722 9.8 TSLP TNF IL6 IL33 IFNG
28 positive regulation of interleukin-6 production GO:0032755 9.8 TSLP TNF IL6 IL33 IL17A IFNG
29 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.78 TNF IL6 IL17A
30 positive regulation of osteoclast differentiation GO:0045672 9.77 TNF IL17A IFNG
31 positive regulation of immunoglobulin production GO:0002639 9.75 IL6 IL33 IL2
32 positive regulation of interleukin-17 production GO:0032740 9.74 IL6 IL2 IL18
33 positive regulation of neuroinflammatory response GO:0150078 9.73 TNF IL6 IL33 IL18
34 astrocyte activation GO:0048143 9.72 TNF IFNG C5AR1
35 negative regulation of amyloid-beta clearance GO:1900222 9.71 TNF IFNG
36 positive regulation of MHC class II biosynthetic process GO:0045348 9.71 IL33 IFNG
37 positive regulation of interleukin-13 production GO:0032736 9.71 TSLP IL33
38 neutrophil activation GO:0042119 9.71 IL18 CXCL8 CCL5
39 positive regulation of interleukin-5 production GO:0032754 9.7 TSLP IL33
40 response to peptidoglycan GO:0032494 9.7 IL6 C5AR1
41 inflammatory response GO:0006954 9.7 TNF TACR1 TAC1 MS4A2 IL6 IL18
42 tachykinin receptor signaling pathway GO:0007217 9.69 TACR1 TAC1
43 vascular endothelial growth factor production GO:0010573 9.68 TNF IL6
44 positive regulation of tissue remodeling GO:0034105 9.68 IL2 IL18
45 positive regulation of STAT cascade GO:1904894 9.67 TSLP IL6
46 positive regulation of interleukin-23 production GO:0032747 9.66 IL17A IFNG
47 detection of abiotic stimulus GO:0009582 9.65 TACR1 TAC1
48 negative regulation of lipid storage GO:0010888 9.65 TNF IL6 CRP
49 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.64 TNF IFNG
50 positive regulation of cellular biosynthetic process GO:0031328 9.64 CXCL8 CCL5

Molecular functions related to Chronic Spontaneous Urticaria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.4 TSLP TNF IL6 IL33 IL31 IL24
2 IgE binding GO:0019863 8.96 MS4A2 FCER1A
Sources

Sources for Chronic Spontaneous Urticaria

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....